An AI breast-cancer screening system evaluated in two countries
Among 25,856 women in the UK and 3,097 in the US, the system reduced false positives by 5.7% (US) and 1.2% (UK), and false negatives by 9.4% and 2.7% in absolute terms compared with radiologists. Trained only on UK data, it also outperformed specialists on US data. Retrospective evaluation (Nature): prospective studies are needed, and clinical deployment is unclear.
Technology: Neural network for mammograms
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Retrospective evaluation on UK (25,856 women) and US (3,097 women) screening mammograms, compared with individual radiologists' decisions; a reader study and a simulated double-reading workflow were also run.
- Still unknown: The authors state prospective studies are required and that how to deploy the system clinically is not yet determined; the US data were enriched; the second-reader scenario was only simulated.
- AI role: Predicted from screening mammograms alone whether a biopsy would later show cancer.
Evidence sources: https://deepmind.google/blog/international-evaluation-of-an-ai-system-for-breast-cancer-screening/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-019-1799-6&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 3668 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.